“…Later on, mitochondrial transfer via TNTs was observed in glioblastomas, multiple myelomas or in an in vitro model of breast cancer, laryngeal cancer, bladder cancer and others ( Pasquier et al, 2013 ; Antanaviciute et al, 2014 ; Osswald et al, 2015 ; Lu et al, 2017 ; Marlein et al, 2019 ; Pinto et al, 2020 ; Salaud et al, 2020 ; D’Aloia et al, 2021 ; Pinto et al, 2021 ). Similarly, cancer cells have been shown to gain malignancy or enhanced resistance to drug treatment, hypoxia or apoptosis via TNTs ( Pasquier et al, 2013 ; Ady et al, 2014 ; Wang and Gerdes, 2015 ; Desir et al, 2016 ; Rustom, 2016 ; Desir et al, 2018 ; Hekmatshoar et al, 2018 ; Sahu et al, 2018 ; Raghavan et al, 2021 ; Kato et al, 2022 ). Moreover, TNTs were identified in hematological malignancies, where inhibition of their formation improved the survival of diseased mice in vivo and enhanced chemosensitivity in vitro ( Polak et al, 2015 ; Wang et al, 2018 ; Marlein et al, 2019 ).…”